SYNCELL Inc., a spatial biology system company, today announced the launch of its early access beta-site program for its innovative spatial omics platform, Microscoop™. As an anchoring strategy to introduce the Microscoop technology to the market, the company is actively seeking and discussing with researchers from different continents who are interested in forming a collaboration with SYNCELL to gain early access to Microscoop for their spatial biomarker projects.

Through the early access program, the beta testing partner can access SYNCELL’s AI-based image processing algorithm development expertise, custom photolabeling reagents, and assay development support to advance their challenging spatial omics projects.

“By placing the beta systems in our customers’ hands, SYNCELL can learn from the real-world user experience and apply these insights to enhance the system’s usability in the commercial product,” said SYNCELL Chief Executive Officer Dr. Jung-Chi Liao. “The goal is to form strong partnerships through the early access program as a prelude to catapult our spatial omics system into the mainstream market.”

Spatial biology is a rapidly growing field. SYNCELL’s Microscoop offers a unique ability to elucidate previously unknown cellular interactions and functions by analyzing the contextual information of cells and tissue sections in a microenvironment. The knowledge has the potential to be applied to deduce new biological mechanisms, identify new drug targets and discover biomarkers for therapy response. For more information on Microscoop beta test program, please contact Betatest@SYNCELL.com

About SYNCELL Inc.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

CONTACT:
Shuyi Liao
SYNCELL, Inc.
Phone +886-2-77505632
Info@syncell.com
Follow SYNCELL on LinkedIn at SYNCELL INC. and tag your posts with #syncell or #microscoop"